At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
ABT-450/r +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study
In Brief
A Phase 2 clinical trial evaluating ABT-450/r, ABT-267, and 2 other interventions for Chronic Hepatitis C. Completed, enrolled 32 participants.
Detailed Summary
A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon alpha-2a and ribavirin in people with hepatitis C virus who did not respond to treatment in a previous AbbVie/Abbott combination study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartDec 2012
Primary CompletionMay 2017
TodayJul 2026
First PostedJun 1, 2012
Enrollment StartDec 18, 2012
Primary CompletionMay 3, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 14.1 years ago
Interventions
ABT-450/rdrug
ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
ABT-267drug
ABT-267 (tablets)
pegylated interferon alpha-2a (pegIFN)drug
pegIFN alpha-2a (syringe)
Ribavirin (RBV)drug
Ribavirin (tablets)